China Eye Valley·Central Incubation Park opened, and a subsidiary of Guangzhou Vesber settled in

China Eye Valley·Central Incubation Park opened, and a subsidiary of Guangzhou Vesber settled in

July 1, China eye · Central Valley Incubator officially opened. Chinese Eye valley – the focus of the whole industry chain of eye health Branch Park rapid rise in a “dragon culture” Legend of the Wenzhou area, the country is becoming a new landmark in the field of life and health.

Chen Weijun, Member of the Standing Committee of the Zhejiang Provincial Party Committee and Secretary of the Wenzhou Municipal Party Committee, Gaoyuan Yao, Deputy Secretary of the Wenzhou Municipal Party Committee and Mayor, Wang Jun, Member of the Standing Committee and Secretary-General of the Wenzhou Municipal Party Committee, Wang Chi, Vice Mayor of Wenzhou Municipal People’s Government, Tang Xiaoshu, Vice Mayor of Wenzhou Municipal People’s Government and other leaders Attended this opening ceremony.

Focus on eye health and create a new height for the life and health industry

China Eye Valley was jointly built by Wenzhou Longwan District (High-tech Zone) and the Eye Optometry Hospital affiliated to Wenzhou Medical University, and the construction was officially launched in September 2018. Relying on the advantages of Wenzhou Medical University and the Eye Optometry Hospital affiliated to Wenzhou Medical University in terms of brand, resources, talents, scientific research, etc., the park strives to build a world-class eye health care center jointly participated by the government, medical institutions, investment institutions, and eye health companies. An industrial chain complex, this is also the only whole-industry chain science and technology park in the national and even global eye health field.

Focusing on the core concept of eye health, China Eye Valley currently has a planned area of ​​1,000 acres. It focuses on promoting projects such as the Central Park Incubation Park and Science and Technology Park, and comprehensively builds a world-class vision technology research and development system, a world-class vision technology academic exchange platform, A world-class high-end medical center for vision, a world-class gathering area for innovative and entrepreneurial talents in vision, and a world-class incubator for vision and high-tech industries. The goal is to become a top national and world-class innovation center for the eye health industry. Up to now, China Eye Valley has completed a fixed asset investment of 536 million yuan.

 

Many well-known companies settled in, including Guangzhou Satellite Vesber subsidiary

At the opening ceremony, China Eye Valley ushered in a new batch of settled companies, and at the same time held the signing ceremony of the Eye Health Innovation Leading Fund. At present, the incubator has attracted 41 enterprises in related fields at home and abroad to settle down, including the world’s top 500 companies Alcon, the national high-tech enterprise Guangzhou Vesber Biological Technology Co., Ltd. subsidiary-Wenzhou Meiyi Biological Technology Co., Ltd. Many well-known companies.

Guangzhou Vesber Biological Technology Co., Ltd. is a national high-tech enterprise focusing on the R&D, production and sales of high-end ophthalmic innovative products. It is located in the Guangdong Medical Valley Industrial Park, the core area of ​​the Guangdong-Hong Kong-Macao Greater Bay Area. The company covers an area of ​​5,000 square meters. Its representative products are The world’s original foldable artificial vitreous balloon, perispheric pressure balloon and high myopia posterior scleral reinforcement device. The subsidiary of Guangzhou Satellite TV Bo-Wenzhou Meiyi Biological Technology Co., Ltd. is mainly engaged in the research and development of post-scleral reinforcement devices for high myopia, providing new technical treatment for patients with high myopia macular split.

In addition, the post-scleral reinforcement device for high myopia won the Excellence Award in the 2019 China Eye Valley-Innovation and Entrepreneurship Global Challenge Finals. Currently, posterior scleral reinforcement is the only surgical method that can alleviate the development of high myopia. However, the current posterior scleral reinforcement surgery has not formed a commercial product. The main reasons are the following two points: First, the reinforcement material is generally allogeneic sclera, but due to cultural, religious beliefs and other factors, the application of allogeneic sclera is relatively restricted; secondly, after reinforcement, due to the barrier effect of the material itself, according to the long-term Observation can cause macular ischemia in the eye and cause severe vision loss again. The development of the posterior scleral reinforcement system for high myopia solves the two limiting factors of posterior scleral reinforcement and will improve the treatment effect of pathological myopia.